73 related articles for article (PubMed ID: 9820067)
21. The effect of four-year hypolipidaemic treatment on the intimal thickness of the common carotid artery in patients with familiar hyperlipidaemia.
Spácil J; Ceska R; Petrásek J; Sobra J
Int Angiol; 1999 Dec; 18(4):313-9. PubMed ID: 10811520
[TBL] [Abstract][Full Text] [Related]
22. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
[TBL] [Abstract][Full Text] [Related]
23. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
[TBL] [Abstract][Full Text] [Related]
24. [Long-term treatment of hyperlipoproteinemia with etofibrate].
Bartz VT; Gatz J; Slotty C; Schröter C; Töle R; Wand P
Fortschr Med; 1993 Sep; 111(25):398-400. PubMed ID: 8406286
[TBL] [Abstract][Full Text] [Related]
25. Normal lipid metabolism, familial hyperlipidaemia, lipid intervention and their benefits.
Koner BC; Goswami K; Kavitha S; Moorthy RS
J Indian Med Assoc; 2003 Feb; 101(2):89-92. PubMed ID: 12841490
[TBL] [Abstract][Full Text] [Related]
26. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Tenenbaum A; Motro M; Fisman EZ; Schwammenthal E; Adler Y; Goldenberg I; Leor J; Boyko V; Mandelzweig L; Behar S
Circulation; 2004 May; 109(18):2197-202. PubMed ID: 15123532
[TBL] [Abstract][Full Text] [Related]
27. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
[TBL] [Abstract][Full Text] [Related]
28. Parabolic relationship between plasma triacylglycerols and LDL-cholesterol in familial combined hyperlipidaemia: the multiple-type hyperlipidaemia explained?
Brouwers MC; de Graaf J; van Greevenbroek MM; Georgieva AM; van der Kallen CJ; Ter Avest E; Stehouwer CD; Stalenhoef AF; de Bruin TW
Clin Sci (Lond); 2008 Mar; 114(5):393-401. PubMed ID: 17953518
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
30. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
31. Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate.
Turay J; Grniaková V; Valka J
Drugs Exp Clin Res; 2000; 26(3):83-8. PubMed ID: 10941600
[TBL] [Abstract][Full Text] [Related]
32. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
Kovács I; Tarján J; Császár A
Orv Hetil; 2001 Apr; 142(15):775-9. PubMed ID: 11367862
[TBL] [Abstract][Full Text] [Related]
33. [Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic].
Ceska R; Stulc T
Cas Lek Cesk; 2000 Jun; 139(12):369-73. PubMed ID: 10953407
[TBL] [Abstract][Full Text] [Related]
34. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.
Ikewaki K; Noma K; Tohyama J; Kido T; Mochizuki S
Int J Cardiol; 2005 Jun; 101(3):441-7. PubMed ID: 15907413
[TBL] [Abstract][Full Text] [Related]
35. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
36. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
[TBL] [Abstract][Full Text] [Related]
37. Diet, smoking, and blood lipids in patients with combined familial hyperlipidaemia.
Králíková E; Ceska R; Rames J
Cent Eur J Public Health; 1999 Feb; 7(1):19-23. PubMed ID: 10084016
[TBL] [Abstract][Full Text] [Related]
38. [Effect of long-term cardiac training on lipids concentration in patients with chronic heart ischemic disease treated with simvastatin].
Kałka D; Sobieszczańska M; Kopka L; Marciniak W; Zawadzka-Bartczak E; Bak A; Popielewicz-Kautz A; Korzeniowska J; Janczak J; Adamus J
Pol Merkur Lekarski; 2007 Feb; 22(128):101-6. PubMed ID: 17598652
[TBL] [Abstract][Full Text] [Related]
39. Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia.
Skoumas I; Masoura C; Pitsavos C; Tousoulis D; Papadimitriou L; Aznaouridis K; Chrysohoou C; Giotsas N; Toutouza M; Tentolouris C; Antoniades C; Stefanadis C
Int J Cardiol; 2007 Oct; 121(2):178-83. PubMed ID: 17188767
[TBL] [Abstract][Full Text] [Related]
40. The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia.
Kovács I; Toldy E; Abel T; Tarján J; Császár A
Endothelium; 2005; 12(4):179-83. PubMed ID: 16162440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
